ENT evaluation and CT imaging demonstrated a large nasopharyngeal mass with biopsy confirming the presence of CD20-positive, diffuse large B-cell lymphoma probably transformed from the preceding follicular lymphoma. He received a cycle of CHOP chemotherapy, consisting of cyclophosphamide, adriamycin, vincristine and prednisone at 80% of the normal dosage, on 9 January 2002 concomitant with imatinib, and it resulted in prolonged neutropenia (Figure 1 ). Imatinib was discontinued and eventually local radiation therapy was given instead. After completion of radiation, imatinib was restarted on 15 March 2002 with the daily dosage of imatinib adjusted to 300 mg per day based on the white blood counts. CT imaging in April 2002 revealed complete resolution of the nasopharyngeal mass. In January 2003, his peripheral blood was negative for BCR-ABL gene rearrangement by polymerase chain reaction. Unfortunately, his disease relapsed locally in February 2003. In view of the previous history of prolonged pancytopenia, the imatinib was discontinued and attenuated Rituxan-CHOP at 67% normal dosage was started. He tolerated the chemotherapy well with prompt marrow recovery and went on to receive second and third cycles of Rituxan-CHOP at 80 and 90% normal dosage, respectively, every 3 weeks. Subsequent CT scans in April 2003 again revealed complete resolution of the nasopharyngeal mass. Owing to the patient's advanced age and concomitant diagnosis of CML, the chemotherapy was discontinued as per the family's request. He was restarted on imatinib 300 mg/day in April 2003 when the peripheral blood turned positive for BCR-ABL. His nasopharyngeal disease again progressed in July 2003 and Rituxan-CHOP at 67% was restarted with him continuing on imatinib. However, the patient developed prolonged pancytopenia and the imatinib was promptly discontinued. His next course of chemotherapy was given in 5-week cycle instead of the usual 3-week cycle. Without concomitant imatinib, his subsequent courses of chemotherapy were successfully given every 3 weeks and with dose escalation (Figure 2 ) without the side effects.
Our case supports the finding of Ruchatz et al and suggests that caution be exercised when imatinib is to be used in combination with systemic chemotherapy. 
Response to Chand et al
Leukemia ( In 1976, the FAB classification considered erythroleukaemia as a proliferation of erythroblasts 450% and a proliferation of blasts 430% without taking into account the predominance of erythroblasts, which rendered the diagnosis rare since the proportion of 30% of blasts was rarely reached. The FAB classification revised its AML6 diagnosis criteria in 1985: after eliminating the erythroid component (that represents at least 50% of the marrow), the proportion of blasts was counted in reference to the remaining population. So AML6 was defined as a proliferation of erythroblasts superior to 50% and of myeloblasts superior to 30%, besides the erythroblasts. The new WHO classification abolishes the barrier between RAEB-t and the acute erythroleukaemias with multilineage dysplasia by lowering to 20% the number of blasts required for the definition of leukaemia.
3 Erythroleukaemia is preceded by a myelodysplastic syndrome in 40% of patients.
4
Multilineage dysplasia is present in 70% of erythroleukaemia.
5
Abnormalities of chromosomes 5 and 7 were found in 65% of erythroleukaemia and this frequency is as high as the frequency found in myelodysplastic syndromes. Thus the differential diagnosis between RAEB-t and AML6 is often difficult because of the overlapping features between myelodysplastic syndrome with excess of erythroblasts and erythroleukaemia.
Our objectives were: (1) to compare RAEB-t and AML6 by their cytologic, karyotypic and evolutive characteristics; and (2) to study the prognostic role of the percentage of erythroblasts in RAEB-t by comparing RAEB-t with less than 50% of erythroblasts and RAEB-t with more than 50% of erythroblasts.
The diagnosis was based on cytologic examination of sternal punction slides of three centres between January 1985 and June 2002: we selected typical AML6 defined by FAB 1985 classification, RAEB-t (with more than 50% of erythroblasts and with less than 50% of erythroblasts). The number of blasts was calculated on the remaining cell population after the withdrawal of the erythroid lineage in RAEB-t with more than 50% of erythroblasts and AML6. The cytology of abnormal cells was described: erythroid dysplasia (macroblasts, basophilic stipplings, lamellar cytoplasm, multinuclearity, caryorrhexis); myeloid dysplasia (hypogranulation, abnormalities of nucleus segmentation); and megakaryocyte dysplasia (hyposegmentation of nuclei, micromegakaryoblasts).
The karyotypes were classified into three groups of risk as defined by the MRC AML10 classification: 6 low risk for the syndrome 5qÀ, the translocation (15; 17), t (8; 21) and inv (16); high risk for the complex karyotypes with more than three clonal abnormalities, deletions of the long arm of chromosomes 5 and 7, der (1; 7), abn (3q), À5, del (5q), À7, t (9; The study reported on 46 patients with the following repartition (Table 1) : 23 AML6, 23 RAEB-t (14 RAEB-t 450% of erythroblasts, nine RAEB-t o50% of erythroblasts); the average age was 65.84 years (range 20-91 years). Myelodysplastic syndromes (RAEB-t) were older than patients having an AML6 (MDS ¼ 65 vs AML6 ¼ 48 years, Po0.005). There was a male preponderance (60%). In all, 18 patients (35%) have been exposed to carcinogenic products. More than half (65%) of the patients having an AML6 had a chemotherapy or a professional exposure, while this proportion reached 34% of patients having a myelodysplastic syndrome (P ¼ 0.038). Of 20 exposed patients, 13 had chemotherapy, radiotherapy or immunosuppressor-like azathioprine. The delay between the exposure to toxics and the disease was identical in the different groups (average ¼ 3478 months).
All patients were admitted for anaemia (median hemoglobin: 8.6 g/dl). There was no significant difference between myelodysplastic syndromes and AML6 for the degree of anaemia. The average number of peripheral erythroblasts were 22%. Only one patient had a hepatosplenomegaly.
On trephine biopsy, the average number of erythroblasts was 26% for RAEB-t o50% of erythroblasts, 61% for RAEB-t 450% of erythroblasts and 59% for AML6. The average number of blasts was 23, 30 and 36%, respectively, for RAEB-t o50% of erythroblasts, RAEB-t 450% of erythroblasts and AML6. In all, 64% of RAEB-t and 100% AML6 had a dyserythropoiesis. The percentage of dysmyelopoiesis and dysmegakaryopoiesis was similar in the three groups. All patients had at least two-lineage dysplasia.
The karyotypes were distributed into three groups according to the MRC classification: good (n ¼ 1), intermediate (n ¼ 20) and bad prognosis groups (n ¼ 16). While the repartition of intermediate prognosis karyotypes were not statistically different between RAEB-t and AML6 (48 vs 35%), there were more bad prognosis karyotypes in AML6 (52%) than in RAEB-t (26%) (w 2 test, Po0.05). Patients (43%) had a karyotype involving the chromosomes 5 or 7. The complete remission (CR) rate in intermediate risk karyotype was 47 vs 31% in bad risk karyotype (NS).
